AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Yue Chen et al.|Cancer Discovery|2017Cited by 457
Serum 2-Hydroxyglutarate Production in <i>IDH1</i>- and <i>IDH2</i>-Mutated De Novo Acute Myeloid Leukemia: A Study by the Acute Leukemia French Association GroupMaxime Janin, Stéphane de Botton, Elena Mylonas et al.|Journal of Clinical Oncology|2013Cited by 117
AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex VivoErica Hansen, Katharine Yen, Cyril Quivoron et al.|Blood|2014Cited by 49
AG-221, an Oral, Selective, First-in-Class, Potent IDH2-R140Q Mutant Inhibitor, Induces Differentiation in a Xenotransplant ModelCyril Quivoron, Virginie Penard‐Lacronique, Muriel D. David et al.|Blood|2014Cited by 19
Supplementary Methods from AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Shinsan M. Su, Jeremy Travins et al.|Unknown|2023Cited by 0